Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
Public ClinicalTrials.gov record NCT00012259. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study Of Troxatyl In Patients With CML Blastic Phase Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of troxacitabine in treating patients who have blast phase chronic myelogenous leukemia.
Study identification
- NCT ID
- NCT00012259
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2000 (Actual)
- Primary completion
- Mar 27, 2002 (Actual)
- Completion
- Mar 27, 2002 (Actual)
- Last update posted
- Jun 10, 2021
2000 – 2002
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer Center and Beckman Research Institute, City of Hope | Duarte | California | 91010-3000 | — |
| USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles | California | 90033-0804 | — |
| Cedars-Sinai Comprehensive Cancer Center | Los Angeles | California | 90048 | — |
| MD Anderson Cancer Center Orlando | Orlando | Florida | 32806 | — |
| Northwestern University Medical Center | Chicago | Illinois | 60611 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637-1470 | — |
| Johns Hopkins Oncology Center | Baltimore | Maryland | 21231-2410 | — |
| Cancer Center of Albany Medical Center | Albany | New York | 12208 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
| Duke Comprehensive Cancer Center | Durham | North Carolina | 27710 | — |
| University of Pennsylvania Cancer Center | Philadelphia | Pennsylvania | 19104-4283 | — |
| Kimmel Cancer Center of Thomas Jefferson University - Philadelphia | Philadelphia | Pennsylvania | 19107-5541 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00012259, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2021 · Synced Oct 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00012259 live on ClinicalTrials.gov.